Dara A Lehman1, Jared M Baeten2, Connor O McCoy3, Julie F Weis4, Dylan Peterson4, Gerald Mbara1, Deborah Donnell5, Katherine K Thomas6, Craig W Hendrix7, Mark A Marzinke7, Lisa Frenkel8, Patrick Ndase6, Nelly R Mugo9, Connie Celum2, Julie Overbaugh10, Frederick A Matsen3. 1. Division of Human Biology Department of Global Health. 2. Department of Global Health Department of Medicine Department of Epidemiology, University of Washington. 3. Division of Public Health Sciences. 4. Division of Human Biology. 5. Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center Department of Global Health. 6. Department of Global Health. 7. Department of Medicine Department of Pharmacology and Molecular Sciences, Johns Hopkins School of Medicine Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland. 8. Seattle Children's Research Institute, Seattle, Washington. 9. Department of Global Health Kenyatta National Hospital, University of Nairobi, Kenya. 10. Division of Human Biology Division of Public Health Sciences.
Abstract
BACKGROUND:Preexposure prophylaxis (PrEP) with emtricitabine plus tenofovir disoproxil fumarate (FTC/TDF) or TDF alone reduces the risk of human immunodeficiency virus (HIV) acquisition. Understanding the risk of antiretroviral resistance selected by PrEP during breakthrough infections is important because of the risk of treatment failure during subsequent antiretroviral use. METHODS: Within the largest randomized trial of FTC/TDF versus TDF as PrEP, plasma samples were tested for HIV with resistance mutations associated with FTC (K65R and M184IV) and TDF (K65R and K70E), using 454 sequencing. RESULTS: Of 121 HIV seroconverters, 25 received FTC/TDF, 38 received TDF, and 58 received placebo. Plasma drug levels in 26 individuals indicated PrEP use during or after HIV acquisition, of which 5 had virus with resistance mutations associated with their PrEP regimen. Among those with PrEP drug detected during infection, resistance was more frequent in the FTC/TDF arm (4 of 7 [57%]), compared with the TDF arm (1 of 19 [5.3%]; P = .01), owing to the FTC-associated mutation M184IV. Of these cases, 3 had unrecognized acute infection at PrEP randomization, and 2 were HIV negative at enrollment. CONCLUSIONS: These results suggest that resistance selected by PrEP is rare but can occur both with PrEP initiation during acute seronegative HIV infection and in PrEP breakthrough infections and that FTC is associated with a greater frequency of resistance mutations than TDF.
RCT Entities:
BACKGROUND: Preexposure prophylaxis (PrEP) with emtricitabine plus tenofovir disoproxil fumarate (FTC/TDF) or TDF alone reduces the risk of human immunodeficiency virus (HIV) acquisition. Understanding the risk of antiretroviral resistance selected by PrEP during breakthrough infections is important because of the risk of treatment failure during subsequent antiretroviral use. METHODS: Within the largest randomized trial of FTC/TDF versus TDF as PrEP, plasma samples were tested for HIV with resistance mutations associated with FTC (K65R and M184IV) and TDF (K65R and K70E), using 454 sequencing. RESULTS: Of 121 HIV seroconverters, 25 received FTC/TDF, 38 received TDF, and 58 received placebo. Plasma drug levels in 26 individuals indicated PrEP use during or after HIV acquisition, of which 5 had virus with resistance mutations associated with their PrEP regimen. Among those with PrEP drug detected during infection, resistance was more frequent in the FTC/TDF arm (4 of 7 [57%]), compared with the TDF arm (1 of 19 [5.3%]; P = .01), owing to the FTC-associated mutation M184IV. Of these cases, 3 had unrecognized acute infection at PrEP randomization, and 2 were HIV negative at enrollment. CONCLUSIONS: These results suggest that resistance selected by PrEP is rare but can occur both with PrEP initiation during acute seronegative HIV infection and in PrEP breakthrough infections and that FTC is associated with a greater frequency of resistance mutations than TDF.
Authors: Valerie F Boltz; Yu Zheng; Shahin Lockman; Feiyu Hong; Elias K Halvas; James McIntyre; Judith S Currier; Margret C Chibowa; Cecelia Kanyama; Apsara Nair; Willis Owino-Ong'or; Michael Hughes; John M Coffin; John W Mellors Journal: Proc Natl Acad Sci U S A Date: 2011-05-16 Impact factor: 11.205
Authors: Michael C Thigpen; Poloko M Kebaabetswe; Lynn A Paxton; Dawn K Smith; Charles E Rose; Tebogo M Segolodi; Faith L Henderson; Sonal R Pathak; Fatma A Soud; Kata L Chillag; Rodreck Mutanhaurwa; Lovemore Ian Chirwa; Michael Kasonde; Daniel Abebe; Evans Buliva; Roman J Gvetadze; Sandra Johnson; Thom Sukalac; Vasavi T Thomas; Clyde Hart; Jeffrey A Johnson; C Kevin Malotte; Craig W Hendrix; John T Brooks Journal: N Engl J Med Date: 2012-07-11 Impact factor: 91.245
Authors: Jared M Baeten; Deborah Donnell; Patrick Ndase; Nelly R Mugo; James D Campbell; Jonathan Wangisi; Jordan W Tappero; Elizabeth A Bukusi; Craig R Cohen; Elly Katabira; Allan Ronald; Elioda Tumwesigye; Edwin Were; Kenneth H Fife; James Kiarie; Carey Farquhar; Grace John-Stewart; Aloysious Kakia; Josephine Odoyo; Akasiima Mucunguzi; Edith Nakku-Joloba; Rogers Twesigye; Kenneth Ngure; Cosmas Apaka; Harrison Tamooh; Fridah Gabona; Andrew Mujugira; Dana Panteleeff; Katherine K Thomas; Lara Kidoguchi; Meighan Krows; Jennifer Revall; Susan Morrison; Harald Haugen; Mira Emmanuel-Ogier; Lisa Ondrejcek; Robert W Coombs; Lisa Frenkel; Craig Hendrix; Namandjé N Bumpus; David Bangsberg; Jessica E Haberer; Wendy S Stevens; Jairam R Lingappa; Connie Celum Journal: N Engl J Med Date: 2012-07-11 Impact factor: 91.245
Authors: Max Lataillade; Jennifer Chiarella; Rong Yang; Steven Schnittman; Victoria Wirtz; Jonathan Uy; Daniel Seekins; Mark Krystal; Marco Mancini; Donnie McGrath; Birgitte Simen; Michael Egholm; Michael Kozal Journal: PLoS One Date: 2010-06-03 Impact factor: 3.240
Authors: Lovemore I Chirwa; Jeffrey A Johnson; Richard W Niska; Tebogo M Segolodi; Faith L Henderson; Charles E Rose; Jin-Fen Li; Michael C Thigpen; Onkabetse Matlhaba; Lynn A Paxton; John T Brooks Journal: AIDS Date: 2014-01-14 Impact factor: 4.177
Authors: Keshet Ronen; Connor O McCoy; Frederick A Matsen; David F Boyd; Sandra Emery; Katherine Odem-Davis; Walter Jaoko; Kishor Mandaliya; R Scott McClelland; Barbra A Richardson; Julie Overbaugh Journal: PLoS Pathog Date: 2013-08-29 Impact factor: 6.823
Authors: Holly Janes; Lawrence Corey; Gita Ramjee; Lindsay N Carpp; Carl Lombard; Myron S Cohen; Peter B Gilbert; Glenda E Gray Journal: AIDS Res Hum Retroviruses Date: 2018-06-19 Impact factor: 2.205
Authors: Peng Xiao; Sanjeev Gumber; Mark A Marzinke; Abhijit A Date; Thuy Hoang; Justin Hanes; Laura M Ensign; Lin Wang; Lisa Rohan; Edward J Fuchs; Craig Hendrix; Francois Villinger Journal: Antimicrob Agents Chemother Date: 2017-12-21 Impact factor: 5.191
Authors: Ross S Milne; Rachel A Silverman; Ingrid A Beck; Jennifer Mckernan-Mullin; Wenjie Deng; Thomas R Sibley; Sandra Dross; James N Kiarie; Samah R Sakr; Robert W Coombs; Michael H Chung; Lisa M Frenkel Journal: AIDS Date: 2019-05-01 Impact factor: 4.177
Authors: Martina Kovarova; Uma Shanmugasundaram; Caroline E Baker; Rae Ann Spagnuolo; Chandrav De; Christopher C Nixon; Angela Wahl; J Victor Garcia Journal: J Antimicrob Chemother Date: 2016-08-01 Impact factor: 5.790
Authors: Julia L Marcus; Jonathan E Volk; Jess Pinder; Albert Y Liu; Oliver Bacon; C Bradley Hare; Stephanie E Cohen Journal: Curr HIV/AIDS Rep Date: 2016-04 Impact factor: 5.071